Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial (Q34223075)

31 July 2017

Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial (English)

1 reference

attention deficit hyperactivity disorder

31 July 2017

0 references

1 reference

4

Fariba Arabgol

1 reference

31 July 2017

Shahin Akhondzadeh

1

1 reference

ORCID Public Data File 2021

author name string

Reza Tavakolian

series ordinal

2

1 reference

31 July 2017

Rozita Davari-Ashtiani

series ordinal

3

1 reference

31 July 2017

Homayoun Amini

series ordinal

5

1 reference

31 July 2017

language of work or name

1 reference

1 August 2003

1 reference

Progress in Neuro-Psychopharmacology & Biological Psychiatry

31 July 2017

1 reference

31 July 2017

27

1 reference

31 July 2017

5

1 reference

31 July 2017

841-845

1 reference

Chronic L-deprenyl treatment alters brain monoamine levels and reduces impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder.

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900117-9

7 January 2021

Parent and Teacher Ratings of ADHD Symptoms: Psychometric Properties in a Community-Based Sample

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900117-9

7 January 2021

A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900117-9

7 January 2021

Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900117-9

7 January 2021

Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900117-9

7 January 2021

Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900117-9

7 January 2021

Deprenyl in attention deficit associated with Tourette's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900117-9

7 January 2021

Treatment of attention deficit hyperactivity disorder in children

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900117-9

7 January 2021

Methylphenidate and growth in hyperactive children. A controlled withdrawal study

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900117-9

7 January 2021

What is attention-deficit/hyperactivity disorder?

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900117-9

7 January 2021

Side effects of methylphenidate and desipramine alone and in combination in children

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900117-9

7 January 2021

Catecholamines in attention-deficit hyperactivity disorder: current perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900117-9

7 January 2021

A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900117-9

7 January 2021

Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900117-9

7 January 2021

Central Stimulant Treatment of Childhood Attention Deficit Hyperactivity Disorder : Issues and Recommendations from a US Perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900117-9

7 January 2021

10.1016/S0278-5846(03)00117-9

Identifiers

DOI

1 reference

31 July 2017

1 reference